| 股票 | 标签 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▴ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 苏轩堂 SXTC | 亏损或困境 | 专业与通用药品制造商 | -0.0 | 0.04 | 0.0% | — | 22% | -28% | 5% | 14% | -337.4% | -35% | -88% | -98% | -100% | -100% | 0% | 0 |
| IM Cannabis IMCC | 亏损或困境 | 专业与通用药品制造商 | -0.0 | -0.30 | 0.0% | — | 18% | -516% | 26% | 111% | -35.2% | +6% | -5% | -71% | -95% | -96% | 3% | 0 |
| Akanda AKAN | 重资产陷阱 | 专业与通用药品制造商 | -0.0 | -0.17 | 0.0% | — | -60% | 0% | 37% | 294% | -371.4% | +0% | -1044% | -76% | -67% | -96% | 2% | 0 |
| BioXcel Therapeutics BTAI | 亏损或困境 | 专业与通用药品制造商 | -0.0 | -0.02 | 0.0% | — | 74% | 0% | 3% | 312% | -2200.3% | -72% | -17% | -93% | -95% | -98% | 2% | 0 |
| PRF Technologies PRFX | 亏损或困境 | 专业与通用药品制造商 | -0.2 | 0.21 | 0.0% | — | -312% | -97% | 0% | 23% | -130.1% | +0% | +66% | -38% | -70% | -86% | 12% | 0 |
| Shuttle Pharmaceuticals SHPH | 亏损或困境 | 专业与通用药品制造商 | 35.0 | 1.07 | 0.0% | 0% | — | -791% | — | 78% | -260.7% | +0% | -28% | -28% | -81% | -90% | 6% | 0 |
| Apimeds Pharmaceuticals APUS | 亏损或困境 | 专业与通用药品制造商 | -0.1 | 0.03 | 0.0% | — | — | -8% | — | 7% | -363.6% | +0% | -332% | -81% | -85% | -85% | 4% | 0 |
| Redhill Biopharma RDHL | 中性 | 专业与通用药品制造商 | 0.0 | 1.03 | 0.0% | — | — | 0% | 5% | 83% | -219.1% | +0% | +95% | -18% | -30% | -50% | 26% | 0 |
| Sunshine Biopharma SBFM | 亏损或困境 | 专业与通用药品制造商 | -0.1 | 0.16 | 0.0% | — | 34% | -26% | 3% | 23% | -121.1% | +4% | -16% | -47% | -91% | -92% | 5% | 0 |
| cbdMD YCBD | 中性 | 专业与通用药品制造商 | 2.1 | 0.65 | 0.0% | 0% | 62% | -95% | 14% | 31% | -41.6% | -2% | +45% | -31% | -65% | -33% | 19% | 0 |
| Sonoma Pharmaceuticals SNOA | 纯久期 | 专业与通用药品制造商 | -1.1 | 0.96 | 0.0% | — | 38% | -85% | 10% | 78% | -40.5% | +37% | +8% | +22% | -64% | -71% | 28% | 0 |
| InMed Pharmaceuticals INM | 亏损或困境 | 专业与通用药品制造商 | -0.7 | 1.07 | 0.0% | — | 34% | -72% | 9% | 14% | -101.2% | +8% | -6% | -9% | +30% | -36% | 55% | 0 |
| Gelteq GELS | 中性 | 专业与通用药品制造商 | -1.7 | 0.98 | 0.0% | — | — | -43% | 0% | 26% | 0.0% | +0% | -85% | +75% | +12% | -42% | 45% | 0 |
| Caring Brands CABR | 亏损或困境 | 专业与通用药品制造商 | -1.2 | -4.83 | 0.0% | — | 56% | -217% | — | 10% | -17.3% | +806% | -314% | +14% | +47% | -69% | 21% | 0 |
| 大自然药业 UPC | 中性 | 专业与通用药品制造商 | -2.9 | 0.36 | 0.0% | — | 35% | -7% | 16% | 19% | -58.8% | -22% | +58% | +11% | +6% | +7% | 22% | 0 |
| Aytu BioPharma AYTU | 轻资产现金牛 | 专业与通用药品制造商 | -0.5 | 0.68 | 0.0% | — | 69% | -58% | 1% | 85% | 7.1% | +2% | +14% | -1% | -15% | -3% | 72% | 0 |
| Biofrontera BFRI | 亏损或困境 | 专业与通用药品制造商 | -3.7 | 4.01 | 0.0% | — | 74% | -141% | 6% | 63% | -33.2% | +12% | +41% | +87% | +182% | +99% | 99% | 0 |
| TherapeuticsMD TXMD | 纯久期 | 专业与通用药品制造商 | -110.5 | 0.94 | 0.0% | — | — | -2% | 7% | 29% | 12.3% | +72% | +74% | +19% | +36% | +105% | 75% | 0 |
| Optimi Health OPTH | 重资产陷阱 | 专业与通用药品制造商 | -3.3 | 2.14 | 0.0% | — | -16% | -46% | 51% | 57% | -13.4% | +6% | +40% | +2% | -30% | +38% | 54% | 0 |
| Rockwell Medical RMTI | 亏损或困境 | 专业与通用药品制造商 | -6.0 | 0.92 | 0.0% | — | 17% | -16% | 17% | 35% | 9.0% | -32% | -1007% | +20% | -4% | -50% | 43% | 0 |
| 惠普森医药 CPHI | 重资产陷阱 | 专业与通用药品制造商 | -2.0 | 0.97 | 0.0% | — | -3% | -21% | 81% | 27% | -0.4% | -8% | +33% | +6% | -32% | -54% | 4% | 0 |
| Incannex Healthcare IXHL | 亏损或困境 | 专业与通用药品制造商 | -0.2 | 0.52 | 0.0% | — | — | -381% | 2% | 34% | -45.6% | +617% | -154% | -17% | -70% | -81% | 16% | 0 |
| 正业生物 ZYBT | 亏损或困境 | 专业与通用药品制造商 | -7.4 | 1.29 | 0.0% | — | 20% | -26% | 40% | 30% | 4.0% | -35% | -743% | +79% | +40% | -80% | 14% | 0 |
| Scynexis SCYX | 亏损或困境 | 专业与通用药品制造商 | -5.8 | 0.79 | 0.0% | — | — | -16% | 1% | 16% | -25.2% | +450% | +60% | +28% | +5% | -28% | 51% | 1 |
| Talphera TLPH | 亏损或困境 | 专业与通用药品制造商 | -5.2 | 4.32 | 0.0% | — | — | -114% | — | 43% | -19.7% | +0% | -10% | +48% | +5% | +46% | 76% | 1 |
| Citius Oncology CTOR | 亏损或困境 | 专业与通用药品制造商 | -1.8 | 1.98 | 0.0% | — | — | -54% | — | 56% | -24.2% | +0% | -17% | +25% | -14% | -53% | 38% | 1 |
| InterCure INCR | 亏损或困境 | 专业与通用药品制造商 | -4.9 | 0.62 | 0.0% | — | 12% | -9% | 12% | 43% | 6.5% | +30% | +42% | +28% | +19% | -33% | 64% | 1 |
| 坎伯兰药业 CPIX | 亏损或困境 | 专业与通用药品制造商 | -9.3 | 5.83 | 0.0% | — | 85% | -12% | 6% | 68% | 0.7% | +18% | +56% | +60% | +120% | +164% | 73% | 1 |
| 博美集团 BGM | 亏损或困境 | 专业与通用药品制造商 | -1.8 | 0.29 | 0.0% | — | 17% | -9% | 9% | 10% | 2.8% | +51% | -1232% | -33% | -92% | -96% | 2% | 1 |
| OrganiGram OGI | 中性 | 专业与通用药品制造商 | 2.6 | 0.47 | 0.0% | 0% | 35% | -8% | 39% | 38% | -12.0% | +58% | +47% | +9% | -31% | -30% | 52% | 2 |
| Lifecore Biomedical LFCR | 中性 | 专业与通用药品制造商 | -5.0 | -4.88 | 0.0% | — | — | -701% | — | 106% | 5.6% | -100% | +100% | -23% | -46% | -40% | 49% | 2 |
| ADC Therapeutics ADCT | 亏损或困境 | 专业与通用药品制造商 | -2.3 | -0.76 | 0.0% | — | 93% | 0% | 2% | 158% | -58.9% | +15% | +10% | +24% | -62% | -61% | 27% | 2 |
| Organogenesis ORGO | 亏损或困境 | 专业与通用药品制造商 | -2.2 | 1.48 | 0.0% | — | 75% | 7% | 20% | 28% | 14.5% | +17% | +4201% | -31% | -67% | -64% | 24% | 2 |
| Journey Medical DERM | 亏损或困境 | 专业与通用药品制造商 | -35.7 | 6.91 | 0.0% | — | 66% | -44% | 0% | 66% | -3.4% | +10% | +22% | +30% | +2% | +12% | 82% | 2 |
| SIGA Technologies SIGA | 中性 | 专业与通用药品制造商 | -82.2 | 1.43 | 0.0% | — | 69% | 11% | 2% | 9% | -8.5% | -32% | -61% | -24% | -39% | -57% | 39% | 2 |
| 极光大麻 ACB | 亏损或困境 | 专业与通用药品制造商 | -2.8 | 0.65 | 0.0% | — | 43% | -25% | 29% | 15% | -8.1% | +15% | -8937% | +20% | -6% | -18% | 59% | 3 |
| Cardiol Therapeutics CRDL | 亏损或困境 | 专业与通用药品制造商 | -8.9 | 14.77 | 0.0% | — | — | -159% | — | 24% | -6.7% | +0% | +3% | +110% | +131% | +110% | 97% | 3 |
| Akebia Therapeutics AKBA | 轻资产现金牛 | 专业与通用药品制造商 | -8.9 | 10.83 | 0.0% | — | 83% | 0% | 1% | 91% | 15.4% | +48% | +92% | +12% | -40% | -69% | 30% | 3 |
| 阿尼卡疗法 ANIK | 中性 | 专业与通用药品制造商 | -77.1 | 2.03 | 0.0% | — | 57% | -7% | 29% | 25% | 2.1% | -6% | +81% | +39% | +116% | +133% | 91% | 3 |
| Emergent BioSolutions EBS | 亏损或困境 | 专业与通用药品制造商 | -1.8 | 0.93 | 0.0% | — | 51% | 10% | 22% | 60% | 30.7% | -29% | +128% | -25% | -50% | -18% | 44% | 3 |
| Alpha Teknova TKNO | 亏损或困境 | 专业与通用药品制造商 | -22.3 | 5.93 | 0.0% | — | 33% | -23% | 33% | 34% | -1.7% | +7% | +36% | +55% | +82% | +59% | 88% | 4 |
| Canopy Growth CGC | 亏损或困境 | 专业与通用药品制造商 | -2.0 | 0.82 | 0.0% | — | 24% | -45% | 21% | 38% | -13.6% | +9% | +47% | -4% | -15% | -28% | 41% | 4 |
| BioAge Labs BIOA | 亏损或困境 | 专业与通用药品制造商 | -4.0 | 1.17 | 0.0% | — | — | -27% | 0% | 8% | -19.9% | +0% | -13% | -38% | -28% | +88% | 37% | 4 |
| Kamada KMDA | 成长兑现 | 专业与通用药品制造商 | 22.5 | 1.83 | 2.9% | 66% | 42% | 8% | 15% | 29% | 7.3% | +12% | +40% | +21% | +27% | +24% | 96% | 5 |
| Evolus EOLS | 亏损或困境 | 专业与通用药品制造商 | -17.5 | -19.87 | 0.0% | — | 66% | 0% | 3% | 110% | -2.5% | +12% | -2% | +38% | +40% | +22% | 100% | 6 |
| Tilray Brands TLRY | 亏损或困境 | 专业与通用药品制造商 | -4.1 | 0.38 | 0.0% | — | 28% | -8% | 21% | 32% | -11.2% | +12% | +95% | -10% | -50% | -60% | 19% | 6 |
| Evotec EVO | 重资产陷阱 | 专业与通用药品制造商 | -2.9 | 0.85 | 0.0% | — | 14% | -12% | 33% | 52% | -19.9% | +12% | +40% | -29% | -40% | -47% | 44% | 7 |
| Aquestive Therapeutics AQST | 亏损或困境 | 专业与通用药品制造商 | -8.1 | -11.84 | 0.0% | — | 58% | 0% | 20% | 121% | -6.8% | -23% | -90% | +34% | -17% | +7% | 71% | 7 |
| Ironwood医药 IRWD | 中性 | 专业与通用药品制造商 | 5.4 | -4.35 | 0.0% | 0% | — | 0% | 3% | 166% | 26.4% | -16% | +2629% | +27% | +26% | +277% | 74% | 7 |
| Collegium Pharmaceutical COLL | 定价权·品牌 | 专业与通用药品制造商 | 18.5 | 2.34 | 0.0% | 0% | 59% | 24% | 1% | 82% | 45.2% | +24% | -9% | -32% | -49% | -38% | 46% | 7 |
| Glass House Brands GLAS | 亏损或困境 | 专业与通用药品制造商 | -11.8 | 11.52 | 0.0% | — | 42% | -47% | 45% | 74% | -2.4% | -9% | -4116% | -32% | +0% | +18% | 64% | 8 |
| Amphastar Pharmaceuticals AMPH | 中性 | 专业与通用药品制造商 | 13.7 | 1.28 | 0.0% | 0% | 50% | 13% | 20% | 52% | 18.7% | -2% | -38% | +14% | -13% | -21% | 78% | 10 |
| Pacira BioSciences PCRX | 成长兑现 | 专业与通用药品制造商 | 75.3 | 1.56 | 0.0% | 0% | 79% | 1% | 12% | 45% | 17.9% | +4% | +107% | +12% | +2% | -2% | 95% | 11 |
| Cronos Group CRON | 中性 | 专业与通用药品制造商 | 17.2 | 1.12 | 0.0% | 0% | 43% | -1% | 12% | 4% | 5.0% | +25% | -107% | +19% | +24% | +32% | 90% | 12 |
| Harrow HROW | 亏损或困境 | 专业与通用药品制造商 | -38.9 | 95.16 | 0.0% | — | 75% | -8% | 3% | 87% | 0.4% | +36% | +71% | +7% | -21% | -3% | 70% | 14 |
| Phibro Animal Health PAHC | 成长兑现 | 专业与通用药品制造商 | 15.7 | 4.03 | 1.2% | 20% | 34% | 30% | 25% | 74% | 4.4% | +17% | +107% | +23% | +3% | -2% | 64% | 16 |
| Xeris制药 XERS | 亏损或困境 | 专业与通用药品制造商 | -87.9 | -160.94 | 0.0% | — | 85% | 0% | 5% | 96% | 3.6% | +44% | +101% | +27% | +9% | +10% | 85% | 16 |
| ANI Pharmaceuticals ANIP | 成长兑现 | 专业与通用药品制造商 | 15.5 | 2.74 | 0.0% | 0% | 61% | 15% | 4% | 62% | 11.6% | +44% | +523% | -13% | -10% | -25% | 72% | 16 |
| Eton Pharmaceutical ETON | 纯久期 | 专业与通用药品制造商 | 149.9 | 35.86 | 0.0% | 0% | 54% | -18% | 0% | 72% | 0.9% | +105% | -20% | +89% | +246% | +229% | 88% | 17 |
| Alvotech ALVO | 亏损或困境 | 专业与通用药品制造商 | -8.7 | -9.40 | 0.0% | — | 60% | 0% | 20% | 119% | -10.5% | +20% | +112% | +28% | +4% | -35% | 58% | 19 |
| 百利高 PRGO | 亏损或困境 | 专业与通用药品制造商 | -1.2 | 0.82 | 7.8% | — | 35% | -39% | 12% | 66% | 9.5% | -3% | -730% | +36% | +15% | -27% | 71% | 21 |
| Trulieve Cannabis TRLV | 亏损或困境 | 专业与通用药品制造商 | -4.9 | 3.04 | 0.0% | — | 60% | -10% | 21% | 58% | 10.5% | -0% | +24% | +5% | +39% | +62% | 91% | 23 |
| Bausch Health BHC | 轻资产现金牛 | 专业与通用药品制造商 | -2.2 | -1.39 | 0.0% | — | 71% | 0% | 8% | 99% | 73.4% | +7% | +267% | +27% | -6% | -10% | 82% | 25 |
| 和黄医药 HCM | 中性 | 专业与通用药品制造商 | 176.1 | 1.95 | 0.0% | 0% | 39% | 46% | 5% | 29% | 0.8% | -13% | +1099% | +30% | +6% | -12% | 77% | 25 |
| 普雷斯蒂奇 PBH | 轻资产现金牛 | 专业与通用药品制造商 | 14.6 | 1.29 | 0.0% | 0% | 55% | 10% | 3% | 46% | 10.1% | -4% | -11% | +6% | -15% | -21% | 74% | 25 |
| Supernus Pharmaceuticals SUPN | 亏损或困境 | 专业与通用药品制造商 | -22.7 | 2.45 | 0.0% | — | 90% | -4% | 1% | 27% | 0.8% | +9% | -152% | -4% | -12% | -5% | 73% | 25 |
| BioCryst制药 BCRX | 轻资产现金牛 | 专业与通用药品制造商 | -7.1 | -5.60 | 0.0% | — | 98% | 0% | 3% | 123% | 14.8% | +94% | +397% | +22% | +28% | +22% | 89% | 25 |
| 脑再生科技 RGC | 亏损或困境 | 专业与通用药品制造商 | -492.1 | 3445.00 | 0.0% | — | — | -55% | — | 16% | -0.1% | +0% | +18% | -66% | -67% | -49% | 10% | 34 |
| Amylyx Pharmaceuticals AMLX | 亏损或困境 | 专业与通用药品制造商 | -24.2 | 15.89 | 0.0% | — | — | -62% | — | 8% | -3.3% | -100% | +52% | +153% | +182% | +227% | 83% | 38 |
| Indivior INDV | 中性 | 专业与通用药品制造商 | 12.5 | -19.92 | 0.0% | 0% | 80% | 0% | 10% | 108% | -1.0% | +4% | +2900% | -8% | -3% | +41% | 82% | 41 |
| Amneal Pharmaceuticals AMRX | 成长兑现 | 专业与通用药品制造商 | 36.3 | 169.32 | 0.0% | 0% | 37% | 0% | 16% | 102% | 3.6% | +8% | +273% | +14% | +38% | +79% | 91% | 56 |
| Kiniksa Pharmaceuticals International KNSA | 纯久期 | 专业与通用药品制造商 | 78.7 | 9.29 | 0.0% | 0% | 55% | 12% | 1% | 26% | 3.0% | +60% | +237% | +58% | +89% | +113% | 94% | 61 |
| Liquidia LQDA | 成长兑现 | 专业与通用药品制造商 | 49.0 | 31.50 | 0.0% | 0% | 92% | -111% | 5% | 86% | 2.7% | +1031% | +46% | +5% | +99% | +145% | 73% | 61 |
| Hims & Hers Health HIMS | 定价权·品牌 | 专业与通用药品制造商 | -43.3 | 19.95 | 0.0% | — | 74% | 25% | 11% | 75% | 4.1% | +59% | +2% | -0% | -15% | -44% | 42% | 65 |
| Lantheus LNTH | 定价权·品牌 | 专业与通用药品制造商 | 24.2 | 5.02 | 0.0% | 0% | 61% | 21% | 7% | 51% | 6.3% | +0% | -25% | +1% | +52% | +88% | 90% | 66 |
| 阿尔凯默斯 ALKS | 中性 | 专业与通用药品制造商 | 121.3 | 4.28 | 0.0% | 0% | 87% | 15% | 12% | 27% | 3.2% | -5% | -34% | +5% | +65% | +62% | 83% | 77 |
| 如瑞迪博士 RDY | 中性 | 专业与通用药品制造商 | 28.5 | 2.46 | 0.7% | 20% | 53% | 12% | 19% | 34% | 4.3% | -6% | -32% | -9% | -14% | -16% | 77% | 100 |
| Elanco Animal Health ELAN | 亏损或困境 | 专业与通用药品制造商 | -59.8 | 1.86 | 0.0% | — | 55% | -4% | 8% | 51% | 5.0% | +6% | -169% | +7% | +8% | +29% | 88% | 122 |
| 神经分泌生物科学 NBIX | 定价权·品牌 | 专业与通用药品制造商 | 22.8 | 4.28 | 0.0% | 0% | 98% | 16% | 8% | 30% | 5.7% | +21% | +40% | -3% | +10% | +8% | 84% | 158 |
| Viatris VTRS | 亏损或困境 | 专业与通用药品制造商 | -45.6 | 1.36 | 2.8% | — | 35% | -21% | 7% | 60% | 12.0% | -3% | -454% | +8% | +39% | +67% | 92% | 194 |
| 美国联合医疗 UTHR | 定价权·品牌 | 专业与通用药品制造商 | 17.5 | 3.27 | 0.0% | 0% | 88% | 20% | 13% | 10% | 8.1% | +11% | +12% | -10% | +0% | +24% | 80% | 209 |
| Zoetis ZTS | 定价权·品牌 | 专业与通用药品制造商 | 12.4 | 9.95 | 2.7% | 34% | 72% | 66% | 22% | 78% | 9.1% | +2% | +7% | -6% | -39% | -49% | 50% | 313 |
| Haleon HLN | 成长兑现 | 专业与通用药品制造商 | 19.6 | 1.91 | 2.0% | 39% | 64% | 10% | 5% | 50% | 8.3% | +5% | +22% | +6% | -3% | +1% | 87% | 422 |
| 梯瓦制药 TEVA | 定价权·品牌 | 专业与通用药品制造商 | 60.6 | 5.46 | 0.0% | 0% | 52% | 21% | 12% | 81% | 4.5% | +4% | +172% | +8% | +16% | +88% | 95% | 424 |
| 武田制药 TAK | 轻资产现金牛 | 专业与通用药品制造商 | -55.1 | 1.21 | 3.2% | — | 65% | -2% | 12% | 52% | 11.1% | -7% | -233% | +18% | +20% | +26% | 98% | 589 |
点表头排序。市值单位亿美元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。